Skip to main content
Natalia Neparidze, MD, Oncology, New Haven, CT

Natalia Neparidze MD

Hematologic Oncology


Associate Professor Research DART Leader, Multiple Myeloma and Gammopathies Program Section of Hematology/Department of Internal Medicine and Yale Cancer Center Yale University School of Medicine

Join to View Full Profile
  • 333 Cedar St# WWW403New Haven, CT 06510

  • Phone+1 203-785-4144

  • Fax+1 203-785-7232

Dr. Neparidze is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 2004 - 2007
  • "Aieti" Highest Medical School
    "Aieti" Highest Medical SchoolClass of 2000

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2010 - 2025
  • NY State Medical License
    NY State Medical License 2010 - 2015
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
    Natalia Neparidze, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
    Natalia Neparidze, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
    Natalia Neparidze, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: